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Introduction 36
Most organisms have evolved an endogenous circadian clock to adjust their metabolic 37 activities to anticipate daily environmental events, such as day/night switches or temperature 38 changes. In mammals, circadian clocks exist in almost every cell and organ. The clock 39 consists of a transcriptional and translational feedback loop (TTFL) in which transcription 40 factors brain and muscle arnt-like protein-1 (BMAL1) and circadian locomotor output cycles 41 kaput (CLOCK) form hetero-dimer complexes (B/C complexes in the following text) and 42 then activate transcription of clock controlled genes (ccgs), including genes encoding PER 43 (PER1, and PER2, and PER3) and CRY proteins (CRY1, and CRY2) (1-3). After translation 44 and post-translational modifications, PERs and CRYs translocate into the nucleus to repress 45 BMAL1/CLOCK complex function (4,5). With such repression, a full clock cycle is 46 completed. A second loop composed of circadian components, such as rev-erb (6) and ror (7) 47 and their coding products is involved in regulating transcription of the arntl1 gene, which 48 encodes the BMAL1 protein. Other clock genes, such ascsnk1d, csnk1e, fblx21, and fblx3, 49 contribute to setting the clock speed (8-11) or in entraining the clockwork (12). 50 to different domains of the BMAL1 protein in order to function as repressors (20) . The 66 photolyase superfamily protein CRYs are more potent than PER proteins for repressing B/C 67 complexes (21, 22, 25) . Partch lab demonstrated that besides binding to BMAL1, CRY1 also 68 associates with CLOCK as a repressor (24). During the repression phase, CRYs bind to B/C 69 complexes at the C terminus of BMAL1 on chromatin, sequestering the binding site from 70 transcriptional co-activators, CBP/p300 (25). Biochemical and cell-based complementation 71 assays suggest that an α-helical domain of CRY1 is required for feedback repression and that 72 the C-terminal domain of CRY1 is dispensable for complementation of the circadian clock in 73 cry1/cry2 double knockout cells (22) . Repression of B/C complexes by CHR has been studied 74 and CHR is reported to be similar to CRY1 with regard to circadian clock regulation, via 75 interacting with the BMAL1 C terminus (23). Anafi et al. reported that CHR functioned at an 76 independent region from (but adjacent to) CRY proteins on the BMAL1 C terminus (14) . 77 However, how repression during the cycle of the circadian clock happens remains unclear, for 78 example, how CHR fulfills its repressor role is elusive. We do not know which region of CHR 79 associates with BMAL1 or the structure of CHR. Thus, to understand how CHR represses 80 B/C complex transcriptional activity, we purified a predicted helical domain of the CHR 81 protein and extended helical domains. Then, we used circular dichroism spectroscopy to 82 confirm secondary structures. We found that the helical domain of CHR is necessary to 83 repress B/C complexes in vitro. Immunoprecipitation 
Circular Dichroism Spectroscopy 144
To verify rich α-helix occupation in the secondary structure of CHR-H, we compared secondary 145 structures of MBP-His 6 , MBP-CHRH-His 6 , and MBP-CHRH3-His 6 with circular dichroism 146 spectroscopy (Biologic/MOS-500). Protein buffer was changed to 50 mM sodium phosphate (pH 147 8.0), and then the protein sample was diluted to 0.1 mg/ml and clarified using by centrifugation 148 (12,000 rpm, 4 , 10 min) before measurement. Each CD spectrum was collected at room ℃ 149 temperature, with a scan rate of 1nm/s; scanning increment, 0.5nm; spectral bandwidth, 1.0nm; 150 Beijing, China), lysates were precleared with Protein G Agarose (P2009, Beyotime, Beijing, China) 180 and then immunoprecipitated with mouse anti-Myc antibodies. After washing five times, the precipitates were resuspended in the 5XSDS loading dye, boiled for 5min, and run on a 12.5% 182 SDS-PAGE gel followed by Western blot analysis. Immunoreactive bands were detected by 183
Typhoon laser scanners (FLA-9500, GE, United States). 184 185
Immunofluorescence and Localization 186
For IF, Hela cells were grown in DMEM supplemented with 10% FBS plus 100 IU/ml penicillin 187 and 0.1mg/ml streptomycin at 37 , 5% CO ℃ 2 . A sterile cover glass was placed into each well of a 188 6-well plate, and then 2 x 10 5 cells per well were seeded 1 day before transfection. When cells 189 reached 70%~90% confluency, they were transfected with Lipo6000™ Transfection Reagent with 190 various combinations of the following constructs (all in pcDNA3.1 (+)/Hygro background): 1,250 191 ng CHR-cpVenus or CHRH3-cpVenus and 1,250 ng 5XMyc-6XHis-hBMAL1, 192 5XMyc-6XHis-hBMAL1-C or 5XMyc-6XHis-hBMAL1-Cs. Twenty-four hours after transfection, 193 cells were washed three times with ice-cold PBS and fixed in 4% paraformaldehyde for 30 min at 194 room temperature. Then cells were permeabilized and blocked with 0.3% TritonX-100 and 195 5%FBS in PBS for 1h at room temperature follow by sequential washing with PBS, and were 196 subjected for incubation using Myc-tag antibody (ab32, UK, abcam, diluted in PBS containing 197 3%BSA) for 1h at room temperature. By following three 5 min PBS washes, cells were 198 immune-stained by Cy3-conjugated antibody (D110172, BBI, Shanghai, China, diluted in PBS 199 containing 1%BSA/0.3%TritonX-100) for 30 min at room temperature. After last three times PBS 200 wash, cells were embedded in Mounting Medium, Antifading (with DAPI, S2110, Solarbio). 201
Analyses and documentation were done with immunofluorescence microscopy (TCS SP5, Leica, 202
Germany).For localization assessment, Hela and NIH 3T3 cells were cultured in the same media, 203 and a sterile cover glass was placed into each well of a 6-well plate, and then 2 x 10 5 cells per well 204 were seeded 1 day before transfection. When cells reached 70%~90% confluency, they were 205 transfected with Lipo6000™ Transfection Reagent with series of cpVenus fused truncations of 206 CHR (all in pcDNA3.1 (+)/Hygro background): 2500 ng 207
CHR-cpVenus/cpVenus-CHR/CHRN-cpVenus/CHRH-cpVenus/CHRC-cpVenus or EGFP. 208
Twenty-four hours after transfection, cells were washed three times with ice-cold PBS and fixed in 209 4% paraformaldehyde for 30 min at room temperature. After three times PBS wash, cells were 210 embedded in Mounting Medium, Anti fading and documented by immunofluorescence microscopy. 212 213 chrono knock out in U2-OS cells 214 chrono -/-bmal1 Luc cell line was generated using the CRISPR/Cas 9 system. Oligonucleotides 215 specific for the target sites of chrono gene loci were designed using the Optimized CRISPR 216
Design tool (www.genomeengineering.org/). The highest quality score sgRNA 217 (CCGCTGCAGGCATCGATCGA) targeted to the exon 1 of chrono (on-target locus: 218 chr1:+150255862) was chosen to insert into the expression vector pX459 219 (pSpCas9{BB}-2A-Puro was a gift from Feng Zhang, Addgene plasmid # 48139). 24 hr after 220 transfection, cells were screened with 2 μg/ml puromycin.Cell line clones were screened by 221 the limiting dilution method. 
Results 231

The helical domain of CHR represses the transcriptional activity of B/C complexes. 232
Since there were neither homologous proteins nor similar protein structures being reported, 233 assessment of CHR amino acid sequences was used to predict its secondary structure. repression as strong as the PER2 protein on the B/C complexes (Fig. 1C ).Furthermore, a 253 series of the extended constructs, CHRH2 (111~262), CHRH3 (111~264) and CHRH4 254 (111~298), were made on the basis of the CHRH and CHRHC. Then, CHRH2, CHRH3 and 255 CHRH4 were applied in the luciferase reporter assay. As the data indicate, CHRH3 and 256 CHRH4 prevented the activation by the B/C complexes, while CHRH2 was not able to 257 repress the activation (Fig. 1D ).According to these results, the functional domain of CHR 258 protein is in the middle of CHR whose significant part is predicted to be an α-helix rich region. 259
Secondary structure of MBP-CHRH/CHRH3 measured by CD spectroscopy. 261
Since we constructed those truncations on the basis of the secondary structure prediction, we 262 further carried out experiments to confirm our prediction. Thus, we first attempted to acquire its 263 tertiary structures through protein crystallization. We tried different tags (GST, 6XHis or MBP) 264 and series of truncations to purify CHR proteins. Eventually, we chose MBP as a tag to purify 265 truncated CHR proteins. However, we were not successful to get information of CHR's tertiary 266 structure through crystallization by now. Based on our luciferase reporter assays, we decided to 267 validate the predicted secondary structure by means of CD spectroscopy. In view of yield and 268 purity, MBP tagged CHRH and CHRH3 were chosen to carry out the CD experiments, The helix-rich domain is necessary for CHR/BMAL1 combining. 280
In light of above luciferase reporter assays, we sought to confirm the interaction between CHR 281 and BMAL1 using co-immunoprecipitation(co-IP). HEK-293T cells were co-transfected with 282 BMAL1 which is fused to a 5Myc-6His tag (5M6HA1, for short of 5Myc-6His-BMAL1) on the 283 N-terminus and CHR which is fused to cpVenus on the C-terminus (CHRV, for short of 284 CHR-cpVenus). The C-terminus fusion with a cpVenus tag did interfere with its cellular 285 localization (Fig. 6A ). In consistent with previous reports that CHR interacts with BMAL1 286 (13-15), CHRV could be co-immunoprecipitated from extracts of HEK-293T cells together with 287 BMAL1 proteins using an anti-Myc antibody (Fig. 3A ). Subsequently, we tested the possible 288 direct interactions between BMAL1 and series of CHR constructs as shown in Figure 1 . In line 289 with previous luciferase reporter assays, the co-IP results indicated that CHRN, CHRH or CHRC alone fused to cpVenus (CHRNV, CHRHV or CHRCV) was not able to interact with 5M6HA1 291 (Fig. 3B ). Again, in agreement with the reporter assays, the detection of CHRHC-cpVenus 292 (CHRHCV) in the co-IP products using anti-Myc antibodies indicated that CHRHC carries the 293 repressive function and the helical domain of CHR is necessary for BMAL1/CHR combining (Fig.  294   3C) . Moreover, in the same system, shorter CHRHC truncated variants (CHRH3 and CHRH4) 295 could be immunoprecipitated by anti-Myc antibodies from extracts of HEK-293T cells 296 co-transfected with 5M6HA1 ( Fig. 3D&3E ), while CHRH2, merely two amino acids shorter than 297 CHRH3, could not be detected (Fig. 3F) . These results signify that the middle region of CHR 298 (111~264) is the minimum area for BMAL1/CHR binding. In summary, it is vital for CHR to 299 perform as a transcriptional repressor that its middle area containing a highly helical domain 300 combining to BMAL1 directly. 301
302
The C-terminus of BMAL1 that is responsible for binding with CHR. 303
A previous study had found a region (514~594) of BMAL1 adjacent to the CRY1 interacting 304 terminus using sequence alignment between C-terminal domains of BMAL1 and BMAL2 305 (14).The full-length CHR was reported to interact with this region, causing interference with 306 binding between B/C complexes and CRE binding protein (CBP) or p300, the transcriptional 307 co-activator of circadian clock pathways (14). However, they did not furnish evidence that the 308 unique region alone has an interaction with CHR by means of immunoprecipitation or other 309 reliable interaction assays. To better understand how CHR interacts with BMAL1 to repress the 310 activity of B/C complexes, we decided to confirm the interaction between CHR and BMAL1C. 311
However, in our data, 5Myc-6His-hBMAL1-C (5M6HA1-C, 514~594) failed to 312 co-immunoprecipitate with the full-length CHR protein (Fig. 4A ).In addition, to solidify our 313 evidences, we also carried out immunofluorescence (IF) assays to test the interactions (Fig. 4H) . 314
As a transcriptional repressor, exotic expressed CHRV located to the nuclei, as detected by the 315 fused fluorescent protein. Our IF assay using anti-Myc antibodies indicated that BMAL1-C 316 located to the cytoplasm. The merged image implied that CHRV and 5M6HA1-Cwere not able to 317 interact with each other (Fig. 4H) , consistent with our co-IP results (Fig. 4A ).Under such 318 circumstance, we believed that there is no sufficient evidence that the right domain of BMAL1 319 amino acids of BMAL1 are required for transcriptional activation (23)and CBP also combines to it 321 (25), we hypothesized that CHR disturbed CBP's co-activation by combining to the last 43 aa of 322 BMAL1(583~626)as well. To test our hypothesis, firstly, we tested whether CHR interacted with 323 the C-terminus of BMAL1. Indeed, 5Myc-6His-hBMAL1-N (5M6HA1-N, 1~490) was not 324 capable of co-immunoprecipitating with CHRV together from extracts of HEK-293T cells (Fig.  325   4B) , while 5Myc-6His-hBMAL1-C longer version (5M6HA1-Cl, 490~626) succeeded (Fig.4C) . 326
Then, we used 5Myc-6His-hBMAL1-C shorter version (5M6HA1-Cs, 579~626), containing the 327 last 43 aa, to pull CHRV down, and it also succeeded in precipitating the CHRV protein (Fig. 4D) . 328
What's more, owing to the fact that CRY1 and CBP compete for BMAL1 TAD domain binding 329 (31, 32), and the fact that IxxLL motif in the TAD α-helix is the major binding site for both 330
CRY1and CBP (25), we constructed L606A and L607A double mutated 5M6HA1 (mut5M6HA1), 331 which destroyed the IxxLL motif (25), to exam whether CHR competes with CBP by combining 332 to TAD domain directly. And the data illustrates that under the ruin of the IxxLL motif in the TAD 333 domain, interaction between BAML1 and CHR disappeared (Fig. 4E) .In other words, CHR, like 334 CRY1,also has a competition with CBP for BMAL1 TAD binding. Since CHRH3 retains the 335 repression function of CHR (Fig. 1D ), we used 5M6HA1-Cs to pull CHRH3V down. Although 336 CHRH3V has been precipitated, compared with the combinations between CHR and BMAL1-Cs 337 and between CHRH3 and BMAL1, there is much weaker combination between CHR3 and 338 BMAL1-Cs (Fig. 4F ). It is probably that the functional domain may need extra parts to stabilize 339 the combination. Therefore, we tested the combination between 5M6HA1-Cs and CHRH4V, 340 which is capable to repress the transcriptional activity evoked by B/C complexes and be 341 immunoprecipitated by BMAL1 as well ( Figs. 1D & 3E) . Then, a stronger binding, compared with 342 CHRH3, has been found between CHRH4 and the C-terminus of BMAL1 (Fig. 4G ). In terms of 343 these data, we suggested that CHRH3 is the minimal domain to exercise as a repressor via being 344 attached to BAML1-Cs, and the coils adjacent to its C-terminus might be regarded as an additional 345 stabilizing part to maintain the binding. Similarly, we confirmed the combination between CHR 346 and the C-terminus of BMAL1 via IF (Fig. 4H) .Consistently, the short construct CHRH3 showed 347 less co-localization, compared to the full-length CHR (Fig. 4H, bottom V.S. middle) . Thus, the 348 repressing domain, CHRH3, is important for interactions between CHR and B/C complexes 349 through the TAD domain at BMAL1's C-terminus..
CRISPR knocking-out of CHR disturbs the circadian timekeeping. 351
As one of the core components of mammalian molecular circadian clock, BMAL1's C-terminal 352 TAD domain determines circadian period (25). Since CHR interacts with BMAL1's TAD domain, 353
we proposed that CHR also contributes to generating the 24 hr period. Previous studies have 354 demonstrated that knocking-out chrono in animals could lengthen the circadian period (13-15), 355 which agrees with our proposal. Nevertheless, it is unclear whether KO of chrono in cultured cells 356 would interfere with the circadian period. Using the CRISPR/Cas9 system (33), the highest score 357 of a 20-nt guide sequence targeting exon 1 of chrono gene was selected as the sgRNA, which 358 is described in the M&M. The chrono gene was knocked out in U2-OS cells which harbor a 359 luciferase reporter under the control of bmal1 promoter, generating chrono -/-bmal1 Luc U2-OS cells. 360
We PCR-amplified the target region from chrono -/-bmal1 Luc genomic DNA, followed by 361 sequencing. The results showed that both chrono alleles were modified, with one allele losing 4 bp 362 and the other allele having 1 bp insertion at the Cas9 cleavage site (Fig. 5A) . These frameshift 363 mutations created premature translation stop codons, which eventually knocked out chrono in 364 U2-OS cells (Fig. 5B ). Comparing to the wild-type U2-OS cells (WT, 22.18  0.068 hr), We have identified the domain of CHR that interacts with BMAL1 to repress the transcription 372 activation of B/C complexes. This domain contains the predicted helix domain and a partial 373 extended coiled region in its C-terminus. These facts make us wonder what the N-terminus of 374 CHR functions. Thus, we constructed two plasmids that cpVenus conjugated at CHR's C-terminus 375 (CHRV) and the N-terminus (VCHR) separately to study the cellular localization of CHR. At first, 376
we checked the location of those proteins in the U2-OS cell line, because CHR is a transcriptional 377 factor located in the nuclei (13), and these two fused proteins were supposed to enter nuclei, too. 378
However, VCHR not CHRV tended to stay at cytoplasm (Fig. 6A ). On account of this 379 phenomenon, we hypothesized that a nuclear localization signal (NLS) may lie in the N-terminus of CHR and cpVenus as a rather huge tag (26KD) may block the nuclear importin via covering the 381 NLS or interfering with its importing partner. However, existing NLS prediction algorithms did 382 not help us find any obvious NLS motif: although CHR is a nuclear protein, there is no specific 383 sequence being rendered as a NLS. Perhaps there is a novel NLS in the N-terminus, so we sought 384 to test whether CHRNV located in the nuclei. Later, we checked the expression of these cpVenus 385 fused truncations via immunofluorescence microscopy. In Hela cell line, we found CHRNV was 386 inclined to locate in the nuclei as much as CHRV, while CHRHV and CHRCV spread evenly in 387 whole cell (Fig. 6B ). Furthermore, we used NIH 3T3 cells to check distributions of these 388 truncations. Compared with distributions of CHRHV and CHRCV, CHRNV has s strong 389 accumulation in the nuclei (Fig. 6C) . Noteworthy, expression of CHRNV was obviously higher 390 than CHRHV and CHRCV's in both cell lines, and these data are consistent with the western blot 391 results (Fig. 3B) . Perhaps, the nuclear-entrance protected CHRN from being degraded. Based on 392 the statistics, we suggested that N-terminus of CHR leads itself to enter the nuclei, though we have 393 not identified the exact NLS signal yet. 394 395 Discussion 397
Analysis of "ciart" or "chrono" in the Uniprot website suggested that this gene appeared in 398 vertebrate during evolution. No homologous gene has been reported, and no structures are 399 described. Thus, to learn about CHR protein, we optimized codon usage to obtain high-yield 400 recombinant proteins (Figs. 2A& 2B) , and then performed circular dichroism spectroscopy 401 experiments. CD spectra analysis confirmed predictions of the helical domain and we purified the 402 helical domain of CHR with high yield. We could not crystalize the region which may need more 403 length optimization. Then, we showed that the domain of CHR mainly composed of this helical 404 proteins could act both ways to repress transcription (Fig.7) . Differences in PER protein activity 421 may depend on specific proteins PERs interacting with, and more work is required to understand 422 these differences. 423
CRYs function as a repressor independently of PER proteins. CRY1 is a stronger repressor 424 than CRY2 during negative feedback (22), while CRY2 may repress transcription cooperatively 425 with PER proteins. CRY1 competes with the transcriptional activator, CBP/p300 for binding to BMAL1 on chromatin (25) . Early studies identified that the last 43 aa of BMAL1 (632 and 626 aa 427 for mouse and human BMAL1, respectively) are required for association with CRY1 (23), and Xu 428 and colleagues found that an L606A/L607A mutant at the BMAL1 C-terminus not only disrupted 429 the association between CRY1 and BMAL1, but also abolished circadian cycling (25). The 430 extreme end of BMAL1 is sequestered by CRY1 from transcriptional co-activators CBP/p300. 431 Therefore, CRY1 proteins repress transcription differently than PER proteins. 432
Using co-IP, we reported that the 579-626aa region of hBMAL1 associates with the helical 433 domain of CHR. Unlike previous reports that CHR binds to a different region of BMAL1 from 434
where CRY proteins bind (14), our data supported that CHR and CRY associates to the same TAD 435 domain of BMAL1 (Fig. 4) . Goriki et al. reported that repression of CHR is HDAC-dependent (13). 436
Collectively, we proposed a model by which PERs, CRYs, and CHR repress B/C transcriptional 437 complexes (Fig. 7) . In brief, PER can either form large complexes to recruit HDAC or displace the 438 B/C complex away from chromatin; CRY and CHR interact with the extreme C-terminal end of 439 BMAL1 to block it from transcriptional co-activators;CHR also recruits HDAC to disrupt the 440 activation. PER proteins associate with the PAS domain of BMAL1 and CLOCK proteins (23), 441 and CRY1 and CHR bind to the C-terminus of BMAL1 (Fig. 7) . Under such interacting modes, 442 PER, CRY, and CHR differentially act as transcriptional repressors to regulate clock functions. 443 predicted helix region plus the C-terminus is able to function as a repressor, rather than the 582 combination of the helix region plus the N-terminus.(D) Luciferase assaysin dicate that CHRH 583 plus extended regions at its C-terminus(CHRH3 and CHRH4) could repress the transcription 584 activation by B/C complexes. Since CHRH3 is 2 amino acids longer than CHRH2 that did not 585 perform the repressive function, this indicates that the helix containing H3 is the minimal domain 586 that functions as a repressor to B/C complexes. At least three independent experimental repeats 587 were done for each luciferase reporter assay. Graphpad Prism 5 was used to generate graphs/plots 588 and perform statistical analysis The cellular extracts were immunoprecipitated with anti-Myc antibodies and detected by using
